Pharvaris (PHVS) Expected to Release Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Pharvaris to announce earnings of ($0.8187) per share and revenue of $2.35 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, analysts expect Pharvaris to post ($3.12) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $0.77 during mid-day trading on Wednesday, reaching $34.01. The company’s stock had a trading volume of 29,833 shares, compared to its average volume of 448,997. The stock has a 50-day moving average of $33.56 and a two-hundred day moving average of $31.04. The stock has a market capitalization of $2.22 billion, a P/E ratio of -11.23 and a beta of -2.48. Pharvaris has a 1-year low of $21.02 and a 1-year high of $43.25.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on PHVS shares. HSBC raised shares of Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. New Street Research set a $60.00 price target on shares of Pharvaris in a research report on Friday, August 14th. Morgan Stanley increased their price objective on Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price target on Pharvaris in a report on Wednesday, September 9th. Finally, Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.53.

Insider Buying and Selling at Pharvaris

In other news, Director Elisabeth Bjork sold 52,500 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the sale, the director owned 15,167 shares of the company’s stock, valued at $574,677.63. The trade was a 77.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Peng Lu sold 100,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the transaction, the president directly owned 64,953 shares of the company’s stock, valued at $2,273,355. The trade was a 60.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 513,102 shares of company stock worth $18,643,666.

Pharvaris Company Profile

Pharvaris N.V. (NASDAQ: PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris’ lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.